| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/26/2006 | US7112597 5-(Substituted thiazolylethoxy)indaneacetic acid derivatives, used in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases |
| 09/26/2006 | US7112589 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases |
| 09/26/2006 | US7112587 e.g., N-Cycloheptyl-N'(1-ethyl-pyrrolidin-2-ylmethyl)-6-(3-fluoro-4-methoxy-phenoxy)-[1,3,5]triazine-2,4-diamine; treating unwanted cellular proliferation, an inflammation mediated disease, or a hyperproliferative disease, or modulating a glycosidase enzyme |
| 09/26/2006 | US7112581 For therapy of cancer and infectious disease |
| 09/26/2006 | US7112580 3-nitrogen-6, 7-dioxygen steroids and uses related thereto |
| 09/26/2006 | US7112579 26,27-Homologated-20-EPI-2-alkyl-19-nor-vitamin D compounds |
| 09/26/2006 | US7112430 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
| 09/26/2006 | US7112426 Human cAMP-dependent protein kinase beta-catalytic subunit |
| 09/26/2006 | US7112421 Nucleic acids encoding BAFF receptor, chimeric proteins and methods and compositions related thereto |
| 09/26/2006 | US7112419 For suppression of hepatocellular carcinoma; genetic engineering |
| 09/26/2006 | US7112415 Method of preparing cell cultures from biological specimens for assaying a response to an agent |
| 09/26/2006 | US7112412 Binding to prostate specific membrane antigen (PSMA) with a radioactive monoclonal antibody or Fab fragments; detecting and kill the cancer cells; bioassay; radiotherapy |
| 09/26/2006 | US7112337 Liposome mixture of a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiological pH, and a lipid joined to a hydrophilic polymer by an aromatic disulfide linkage, associated with a nucleic |
| 09/26/2006 | US7112324 CD 19×CD3 specific polypeptides and uses thereof |
| 09/26/2006 | US7112318 Phosphonium or quaternary ammonium salts labeled with 11C, 18F,76Br, or 123I; for positron emission tomography; capable of measuring mitochondrial surface potential; localize into dysfunctional mitochondria |
| 09/26/2006 | US7112317 Administering a targeting agent operatively attached to a therapeutic agent; the targeting agent recognizes and binds to a tumor-associated endothelial cell marker. |
| 09/26/2006 | CA2283464C Functional dna clone for hepatitis c virus (hcv) and uses thereof |
| 09/26/2006 | CA2279317C O-sulfated bacterial polysaccharides |
| 09/26/2006 | CA2135312C Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase as a modality in cancer therapy |
| 09/21/2006 | WO2006099480A2 Stress proteins and peptides and methods of use thereof |
| 09/21/2006 | WO2006099474A1 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites |
| 09/21/2006 | WO2006099231A1 Pyrimidine derivatives for treatment of hyperproliferative disorders |
| 09/21/2006 | WO2006099175A2 Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer |
| 09/21/2006 | WO2006099132A1 Azacytosine analogs and derivatives |
| 09/21/2006 | WO2006099095A2 Ribosome inhibitors as inhibitors of tyrosyl-dna-phosphodiesterase |
| 09/21/2006 | WO2006099015A2 Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders |
| 09/21/2006 | WO2006098962A1 Compounds for inhibiting ksp kinesin activity |
| 09/21/2006 | WO2006098628A1 Oral dosage forms of gemcitabine derivatives |
| 09/21/2006 | WO2006098496A1 Coordination compound composed of diaminocyclohexane platinum (ii) and block copolymer and anti-cancer agent comprising the same |
| 09/21/2006 | WO2006098465A1 Prophylactic/therapeutic agent for cancer |
| 09/21/2006 | WO2006098355A1 Anticancer compound, intermediate therefor, and processes for producing these |
| 09/21/2006 | WO2006098304A1 Novel secretory protein derived from pituitary cell and use of the same |
| 09/21/2006 | WO2006098074A1 Apoptosis inducing agent for prostate carcinoma cell |
| 09/21/2006 | WO2006097774A1 Synthetic peptides containing unnatural adamantane-related amino acids for use as antitumour drugs |
| 09/21/2006 | WO2006097730A1 Analogues of the azinomycins as anti-tumour agents and as prodrugs |
| 09/21/2006 | WO2006097625A1 Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same |
| 09/21/2006 | WO2006097474A1 N-sulphonylpyrroles and their use as histone deacetylase inhibitors |
| 09/21/2006 | WO2006097460A1 Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them |
| 09/21/2006 | WO2006097459A1 Method for preventing cardiovascular diseases |
| 09/21/2006 | WO2006097337A2 11β-HYDROXYSTEROID DEHYDROGENASES |
| 09/21/2006 | WO2006097323A1 TETRAHYDRO-ISOQUINOLIN-l-ONES FOR THE TREATMENT OF CANCER |
| 09/21/2006 | WO2006097273A1 Compounds having immunomodulator activity |
| 09/21/2006 | WO2006097262A1 Semi-synthetic taxane derivatives with antitumor activity |
| 09/21/2006 | WO2006097261A1 Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments |
| 09/21/2006 | WO2006097176A1 Phthalazinones |
| 09/21/2006 | WO2006096953A1 Use of crotamine, kit and composition |
| 09/21/2006 | WO2006066913A3 Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors |
| 09/21/2006 | WO2006063294A3 Novel inhibitors of histone deacetylase for the treatment of disease |
| 09/21/2006 | WO2006055760A9 Triazole compounds that modulate hsp90 activity |
| 09/21/2006 | WO2006049957A3 Method for treating glioma |
| 09/21/2006 | WO2006046734A3 Novel aminopyridine derivatives having selective aurora-a inhibitory effect |
| 09/21/2006 | WO2006044826A3 Thiophens and their use as anti-tumor agents |
| 09/21/2006 | WO2006002422A9 Compounds for immunopotentiation |
| 09/21/2006 | WO2004089282A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 09/21/2006 | US20060212109 Delivery of therapeutic capable agents |
| 09/21/2006 | US20060211764 Cell activator, process for producing cell activator and apparatus therefor |
| 09/21/2006 | US20060211714 Quinazoline derivatives and their use in the treatment of cancer |
| 09/21/2006 | US20060211696 IMIDAZO[1,2-b]PYRIDAZINE COMPOUND |
| 09/21/2006 | US20060211694 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease |
| 09/21/2006 | US20060211674 Combination comprising a vasculostatic compound and an alkylating agent for the treatment of a tumor |
| 09/21/2006 | US20060211664 Method for treating erectile dysfunction and increasing libido in men |
| 09/21/2006 | US20060211661 24 hydroxyvitamin d, analogs and uses thereof |
| 09/21/2006 | US20060211651 Persulfated oligosaccharide acting on selectins and chemokine |
| 09/21/2006 | US20060211646 Formulations with anti-tumour action |
| 09/21/2006 | US20060211638 Exon 1 ss of pdgf alpha gene and utilization thereof |
| 09/21/2006 | US20060211637 Methods of down regulating target gene expression in vivo by introduction of interfering rna |
| 09/21/2006 | US20060211618 Polynucleotides and polypeptides of the erythropoietin gene |
| 09/21/2006 | US20060211607 Somatostatin-dopamine chimeric analogs |
| 09/21/2006 | US20060211091 MAGE-A3 peptides presented by HLA class II molecules |
| 09/21/2006 | US20060211090 Human cDNAs and proteins and uses thereof |
| 09/21/2006 | US20060211058 Diagnosis and treatment of malignant neoplasms |
| 09/21/2006 | US20060211025 Molecular signatures of commonly fatal carcinomas |
| 09/21/2006 | US20060210656 Synergistic Effects of Nuclear Transcription Factor NF-kB Inhibitors and Anti-Neoplastic Agents |
| 09/21/2006 | US20060210618 Polyglycrine based phospholipid containing amide groups; surfactant, solubilizer, dispersant for cosmetics, lipid membrane for drug delivery systems |
| 09/21/2006 | US20060210591 Immunization of an individual against carcinomas and the preliminary stages thereof |
| 09/21/2006 | US20060210576 Method for treating or preventing metastasis of colorectal cancers |
| 09/21/2006 | US20060210575 Cytotoxic protein and utilization thereof |
| 09/21/2006 | US20060210571 Engineering antibodies that bind irreversibly |
| 09/21/2006 | US20060210564 Novel diabody-type bispecific antibody |
| 09/21/2006 | US20060210561 Dosages for treatment with anti-EGFR antibodies |
| 09/21/2006 | US20060210560 TNF receptor action modulaton |
| 09/21/2006 | US20060210535 Means for regulating the expression of human isoforms of ant |
| 09/21/2006 | US20060210531 Agent eleveting dendritic cell precursor level in blood |
| 09/21/2006 | US20060210477 Therapeutic agent for cancer |
| 09/21/2006 | US20060210473 VEGF-conjugate combined methods for tumor vasculature targeting and tumor treatment |
| 09/21/2006 | DE102005012681A1 New 1,5-dihydro-pyrrol-2-one compounds are HDM2 inhibitors, useful for treating e.g. stroke, heart infarct, ischemia, multiple sclerosis, Alzheimer's disease, degenerative disease, viral infection and cancer |
| 09/21/2006 | DE102005011822A1 Phthalazinone Phthalazinones |
| 09/21/2006 | CA2606329A1 Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders |
| 09/21/2006 | CA2601897A1 Semi-synthetic taxane derivatives with antitumor activity |
| 09/21/2006 | CA2601503A1 Phenol derivatives and their use to modulate pkb activity |
| 09/21/2006 | CA2601425A1 Novel dihydropyrimidine derivatives and their use as anti-cancer agents |
| 09/21/2006 | CA2601257A1 Pyrimidine derivatives for treatment of hyperproliferative disorders |
| 09/21/2006 | CA2600985A1 1-subsituted-3,4-dihydro-pthalazin-4-ones as eg5 inhibitors |
| 09/21/2006 | CA2600822A1 Method for preventing cardiovascular diseases |
| 09/21/2006 | CA2600568A1 Prophylactic/therapeutic agent for cancer |
| 09/21/2006 | CA2600528A1 Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them |
| 09/21/2006 | CA2600505A1 Anti-mesothelin antibodies |
| 09/21/2006 | CA2600446A1 Novel liposome compositions |
| 09/21/2006 | CA2600399A1 Oral dosage forms of gemcitabine derivatives |
| 09/21/2006 | CA2599901A1 Compounds for inhibiting ksp kinesin activity |